ReP USP - Resultado da busca

Artigo de periodico
Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms (2022)
Cacemiro, Maira da Costa ; Cominal, Juçara Gastaldi ; Pereira, Luiz Miguel ; Berzoti-Coelho, Maria Gabriela ; Berbel, Giovana Michelassi; Baroni, Luciana ; Pereira, Tathiane Maistro Malta ; Tognon, Raquel; Nunes, Natália de Souza ; Souto, Elizabeth Xisto; Pontes, Lorena Lobo de Figueiredo ; Natsui, Ana Patrícia Yatsuda ; Castro, Fabíola Attié de
Fonte: Medical Oncology. Unidades: FCFRP, FMRP, ESALQ, FFCLRP, IQ
Assuntos: APOPTOSE, EXPRESSÃO GÊNICA, HIPOTÁLAMO, NEOPLASIAS, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CACEMIRO, Maira da Costa et al. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. Medical Oncology, v. 39, n. 5, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1007/s12032-022-01696-x. Acesso em: 18 maio 2024.
APA
Cacemiro, M. da C., Cominal, J. G., Pereira, L. M., Berzoti-Coelho, M. G., Berbel, G. M., Baroni, L., et al. (2022). Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. Medical Oncology, 39( 5), 1-11. doi:10.1007/s12032-022-01696-x
NLM
Cacemiro M da C, Cominal JG, Pereira LM, Berzoti-Coelho MG, Berbel GM, Baroni L, Pereira TMM, Tognon R, Nunes N de S, Souto EX, Pontes LL de F, Natsui APY, Castro FA de. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms [Internet]. Medical Oncology. 2022 ; 39( 5): 1-11.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s12032-022-01696-x
Vancouver
Cacemiro M da C, Cominal JG, Pereira LM, Berzoti-Coelho MG, Berbel GM, Baroni L, Pereira TMM, Tognon R, Nunes N de S, Souto EX, Pontes LL de F, Natsui APY, Castro FA de. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms [Internet]. Medical Oncology. 2022 ; 39( 5): 1-11.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s12032-022-01696-x
Artigo de periodico
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis (2020)
Viegas, Juliana Santos Rosa ; Praça, Fabíola Silva Garcia ; Caron, Angelo Luis ; Suzuki, Isabella Luiz ; Silvestrini, Ana Vitória Pupo ; Medina, Wanessa Silva Garcia; Del Ciampo, Luiz Antonio ; Kravicz, Marcelo Henrique; Bentley, Maria Vitória Lopes Badra
Fonte: Drug Delivery and Translational Research. Unidades: FCFRP, FMRP
Assuntos: NANOPARTÍCULAS, PSORÍASE, MEDICAMENTO TÓPICO, CITOCINAS, GENÉTICA, FÁRMACOS IMUNOSSUPRESSORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIEGAS, Juliana Santos Rosa et al. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug Delivery and Translational Research, v. 10, n. 3, p. 646-660, 2020Tradução . . Disponível em: https://doi.org/10.1007/s13346-020-00723-6. Acesso em: 18 maio 2024.
APA
Viegas, J. S. R., Praça, F. S. G., Caron, A. L., Suzuki, I. L., Silvestrini, A. V. P., Medina, W. S. G., et al. (2020). Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug Delivery and Translational Research, 10( 3), 646-660. doi:10.1007/s13346-020-00723-6
NLM
Viegas JSR, Praça FSG, Caron AL, Suzuki IL, Silvestrini AVP, Medina WSG, Del Ciampo LA, Kravicz MH, Bentley MVLB. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis [Internet]. Drug Delivery and Translational Research. 2020 ; 10( 3): 646-660.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s13346-020-00723-6
Vancouver
Viegas JSR, Praça FSG, Caron AL, Suzuki IL, Silvestrini AVP, Medina WSG, Del Ciampo LA, Kravicz MH, Bentley MVLB. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis [Internet]. Drug Delivery and Translational Research. 2020 ; 10( 3): 646-660.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s13346-020-00723-6
Artigo de periodico
Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats (2019)
Porto, Hellen Karine Paes; Grando, Marcella Daruge; Ramalho, Leandra Naira Zambelli ; Valadares, Marize Campos ; Bendhack, Lusiane Maria ; Batista, Aline Carvalho ; Rocha, Matheus Lavorenti
Fonte: Archives of Toxicology. Unidades: FCFRP, FMRP
Assuntos: SISTEMA CARDIOVASCULAR, PARACETAMOL, ESTRESSE OXIDATIVO, VASODILATAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PORTO, Hellen Karine Paes et al. Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats. Archives of Toxicology, v. 93, n. 7, p. 1955-1964, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00204-019-02463-0. Acesso em: 18 maio 2024.
APA
Porto, H. K. P., Grando, M. D., Ramalho, L. N. Z., Valadares, M. C., Bendhack, L. M., Batista, A. C., & Rocha, M. L. (2019). Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats. Archives of Toxicology, 93( 7), 1955-1964. doi:10.1007/s00204-019-02463-0
NLM
Porto HKP, Grando MD, Ramalho LNZ, Valadares MC, Bendhack LM, Batista AC, Rocha ML. Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats [Internet]. Archives of Toxicology. 2019 ; 93( 7): 1955-1964.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s00204-019-02463-0
Vancouver
Porto HKP, Grando MD, Ramalho LNZ, Valadares MC, Bendhack LM, Batista AC, Rocha ML. Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats [Internet]. Archives of Toxicology. 2019 ; 93( 7): 1955-1964.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s00204-019-02463-0
Artigo de periodico
Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers (2016)
Antunes, Natalícia de Jesus; Wichert-Ana, Lauro; Coelho, Eduardo Barbosa; Pasqua, Oscar Della; Alexandre Junior, Veriano; Takayanagui, Osvaldo Massaiti; Tozatto, Eduardo; Marques, Maria Paula; Lanchote, Vera Lúcia
Fonte: European Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Assuntos: ANTICONVULSIVANTES, FARMACOCINÉTICA CLÍNICA, MOLÉCULA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANTUNES, Natalícia de Jesus et al. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. European Journal of Clinical Pharmacology, v. 72, n. 2, p. 195-201, 2016Tradução . . Disponível em: https://doi.org/10.1007/s00228-015-1970-4. Acesso em: 18 maio 2024.
APA
Antunes, N. de J., Wichert-Ana, L., Coelho, E. B., Pasqua, O. D., Alexandre Junior, V., Takayanagui, O. M., et al. (2016). Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. European Journal of Clinical Pharmacology, 72( 2), 195-201. doi:10.1007/s00228-015-1970-4
NLM
Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Junior V, Takayanagui OM, Tozatto E, Marques MP, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers [Internet]. European Journal of Clinical Pharmacology. 2016 ; 72( 2): 195-201.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s00228-015-1970-4
Vancouver
Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Junior V, Takayanagui OM, Tozatto E, Marques MP, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers [Internet]. European Journal of Clinical Pharmacology. 2016 ; 72( 2): 195-201.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s00228-015-1970-4
Artigo de periodico
Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers (2008)
Rocha, Adriana; Coelho, Eduardo Barbosa; Moussa, Soraia A. P.; Lanchote, Vera Lúcia
Fonte: European Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Assuntos: GASTROENTEROLOGIA, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROCHA, Adriana et al. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. European Journal of Clinical Pharmacology, v. 64, n. 9, p. 901-906, 2008Tradução . . Disponível em: https://doi.org/10.1007/s00228-008-0510-x. Acesso em: 18 maio 2024.
APA
Rocha, A., Coelho, E. B., Moussa, S. A. P., & Lanchote, V. L. (2008). Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. European Journal of Clinical Pharmacology, 64( 9), 901-906. doi:10.1007/s00228-008-0510-x
NLM
Rocha A, Coelho EB, Moussa SAP, Lanchote VL. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers [Internet]. European Journal of Clinical Pharmacology. 2008 ; 64( 9): 901-906.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s00228-008-0510-x
Vancouver
Rocha A, Coelho EB, Moussa SAP, Lanchote VL. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers [Internet]. European Journal of Clinical Pharmacology. 2008 ; 64( 9): 901-906.[citado 2024 maio 18 ] Available from: https://doi.org/10.1007/s00228-008-0510-x

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Assuntos

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada